ubmslateCN-logo-ubm

CN Mobile Logo

Search form

Topics:
Andy Slavitt

Former CMS Administrator Andy Slavitt said the fact a majority of physicians hate their current technology means there’s room for improvement in health IT.

Dr. Mark Werner

At HIMSS17, a clinical leadership consultant advises physicians to not be scared of MACRA, but instead, see it as a great opportunity for transformative change.

©Goodluz/Shutterstock.com

When preparing for a meeting, be sure that you are confident and knowledgeable in your material, and that your delivery is positive.

This video highlights emerging data on genomic markers of response to neoadjuvant chemotherapy for patients with bladder cancer.

In this interview we discuss a new study that looked at the outcomes of patients with small renal masses who were followed with active surveillance.

This video examines a new study that looked at genomic alterations in the circulating tumor DNA of patients with metastatic RCC during first- and second-line therapies.

Genomic subtyping of muscle-invasive bladder cancer could inform decisions on when best to use neoadjuvant cisplatin-based chemotherapy, according to a retrospective, non-randomized study.

A single cycle of adjuvant bleomycin, etoposide, and cisplatin (BEP) chemotherapy might reduce recurrence rates for nonseminomatous or combined germ cell tumors of the testis.

Pages

Subscribe to Cancer Network RSS

By clicking Accept, you agree to become a member of the UBM Medica Community.